Flibanserin (Addyi®) for hypoactive sexual desire disorder in postmenopausal women

The FDA-approved Prescribing Information (last reviewed on April 13, 2019) states that it is “indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: – A co-existing medical or psychiatric condition -Problems…